Shenzhen Kangtai Biological Products Co Ltd Total Assets
Shenzhen Kangtai Biological Products Co Ltd total assets. Based on the latest financial reports, Shenzhen Kangtai Biological Products Co Ltd (300601) holds total assets worth CN¥13.93 Billion CNY (≈ $2.04 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 300601 market cap for the company's overall valuation and market capitalisation.
Total Assets of Shenzhen Kangtai Biological Products Co Ltd (2012–2025)
Total assets of Shenzhen Kangtai Biological Products Co Ltd from 2012 to 2025. This chart illustrates how Shenzhen Kangtai Biological Products Co Ltd's total assets have evolved over time, based on quarterly financial data. See Shenzhen Kangtai Biological Products Co stock quote for real-time trading data and today's change.
Shenzhen Kangtai Biological Products Co Ltd - Asset Composition Analysis
Shenzhen Kangtai Biological Products Co Ltd Total Assets Breakdown (December 2025)
Shenzhen Kangtai Biological Products Co Ltd total assets breakdown as of December 2025. Shenzhen Kangtai Biological Products Co Ltd's total assets of CN¥13.93 Billion consist of 42.5% current assets and 57.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 1.8% |
| Accounts Receivable | CN¥2.58 Billion | 18.3% |
| Inventory | CN¥681.09 Million | 4.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥585.39 Million | 4.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Shenzhen Kangtai Biological Products Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 300601 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Kangtai Biological Products Co Ltd's current assets represent 42.5% of total assets in 2025, an increase from 40.2% in 2012.
- Cash Position: Cash and equivalents constituted 1.8% of total assets in 2025, down from 19.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 19.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 18.3% of total assets.
Shenzhen Kangtai Biological Products Co Ltd Competitors by Total Assets
Key competitors of Shenzhen Kangtai Biological Products Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Shenzhen Kangtai Biological Products Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.06 | 2.66 | 3.44 |
| Quick Ratio | 2.72 | 2.37 | 2.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.17 Billion | CN¥3.80 Billion | CN¥4.94 Billion |
Shenzhen Kangtai Biological Products Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shenzhen Kangtai Biological Products Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.48 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | -3.2% |
| Total Assets | CN¥14.10 Billion |
| Market Capitalization | $2.08 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Kangtai Biological Products Co Ltd's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shenzhen Kangtai Biological Products Co Ltd's assets decreased by 3.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shenzhen Kangtai Biological Products Co Ltd (2012–2025)
The table below shows the annual total assets of Shenzhen Kangtai Biological Products Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥14.10 Billion ≈ $2.06 Billion |
-3.22% |
| 2024-12-31 | CN¥14.56 Billion ≈ $2.13 Billion |
-3.46% |
| 2023-12-31 | CN¥15.09 Billion ≈ $2.21 Billion |
+9.42% |
| 2022-12-31 | CN¥13.79 Billion ≈ $2.02 Billion |
-2.56% |
| 2021-12-31 | CN¥14.15 Billion ≈ $2.07 Billion |
+47.62% |
| 2020-12-31 | CN¥9.58 Billion ≈ $1.40 Billion |
+142.50% |
| 2019-12-31 | CN¥3.95 Billion ≈ $578.36 Million |
+18.31% |
| 2018-12-31 | CN¥3.34 Billion ≈ $488.87 Million |
+51.12% |
| 2017-12-31 | CN¥2.21 Billion ≈ $323.50 Million |
+38.09% |
| 2016-12-31 | CN¥1.60 Billion ≈ $234.26 Million |
+20.02% |
| 2015-12-31 | CN¥1.33 Billion ≈ $195.18 Million |
-0.61% |
| 2014-12-31 | CN¥1.34 Billion ≈ $196.39 Million |
+21.25% |
| 2013-12-31 | CN¥1.11 Billion ≈ $161.97 Million |
-2.62% |
| 2012-12-31 | CN¥1.14 Billion ≈ $166.34 Million |
-- |
About Shenzhen Kangtai Biological Products Co Ltd
Shenzhen Kangtai Biological Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of human vaccines in China and internationally. The company offers 13-valent pneumococcal polysaccharide conjugate vaccines (TT/DT); varicella vaccines (freeze-dried); hepatitis B vaccines; 23-valent pneumococcal polysaccharide vaccines; diphtheria tetanus ace… Read more